Related Experiment Videos
An attempt at topical DNCB immunomodulation in advanced malignant melanoma
1Department of Medical Oncology, Maria Sklodowska Curie Memorial Institute, Krakow, Poland.
Abstract:
Nineteen patients with malignant melanoma metastatic to the skin, subcutaneous tissue or lymph nodes were treated with DNCB applied to the lesion. None of the patients was amenable to any other form of treatment. During the 20-month follow-up, complete remission occurred in 3 patients and partial remission in 3 patients, 1 patient showed stabilization of the disease, and in the remaining 12 not even transient improvement was observed.
Insights
Topical DNCB treatment showed limited efficacy for advanced malignant melanoma. Of 19 patients with metastatic melanoma, only 6 experienced remission or stabilization.
Area of Science:
- Oncology
- Dermatology
- Immunotherapy
Background:
- Malignant melanoma is a serious skin cancer with limited treatment options for metastatic disease.
- DNCB (dinitrochlorobenzene) is a chemical agent with known immunomodulatory properties.
Purpose of the Study:
- To evaluate the efficacy of topical DNCB as a treatment for malignant melanoma metastatic to the skin, subcutaneous tissue, or lymph nodes.
- To assess treatment response in patients with advanced melanoma refractory to other therapies.
Main Methods:
- Nineteen patients with advanced malignant melanoma received topical DNCB treatment applied directly to lesions.
- Patients were monitored over a 20-month follow-up period.
Main Results:
- Complete remission was observed in 3 patients (15.8%).
- Partial remission occurred in 3 patients (15.8%).
- Disease stabilization was noted in 1 patient (5.3%), while 12 patients (63.2%) showed no improvement.
Conclusions:
- Topical DNCB demonstrated limited therapeutic benefit in this cohort of advanced melanoma patients.
- Further research is needed to explore DNCB's potential role or optimize its application in melanoma treatment.